Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TNFR2 monoclonal antibody BI-1808

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against tumor necrosis factor Receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential antineoplastic activity. Upon administration, anti-TNFR2 monoclonal antibody BI-1808 targets and binds to TNFR2 on tumor-associated regulatory T cells (Tregs) in the tumor microenvironment (TME), thereby preventing TNFR2-mediated signaling. This depletes intra-tumoral Tregs, induces and expands intra-tumoral CD8+ T cells, thereby enhancing T-cell-mediated immune responses against tumor cells. TNFR2 plays a role in tumor necrosis factor signaling, tumor expansion and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BI 1808
BI-1808
BI1808
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search